| Symbol | SION |
|---|---|
| Name | SIONNA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 21 HICKORY DRIVE,SUITE 500, WALTHAM, Massachusetts, 02451, United States |
| Telephone | 617-819-2020 |
| Fax | — |
| — | |
| Website | https://www.sionnatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002036042 |
| Description | Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the treatment paradigm for cystic fibrosis (CF) patients. The company focuses on developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. Their goal is to deliver differentiated medicines that can restore CFTR function as close to normal as possible by directly stabilizing CFTRs nucleotide-binding domain 1 (NBD1). Sionna is currently conducting Phase 1 trials for two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with their NBD1 stabilizers to improve CFTR function, as observed in preclinical models. Additional info from NASDAQ: |
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
Read moreSION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics
Read moreSION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
Read moreSionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION)
Read more(70% Positive) SIONNA THERAPEUTICS, INC. (SION) Provides Update on medicines for healthy subjects
Read moreSionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
Read moreFitzpatrick Jennifer 🟡 adjusted position in 10.2K shares (1 derivative) of Sionna Therapeutics, Inc. (SION) at $43.60 Transaction Date: Jul 06, 2026 | Filing ID: 000006
Read more📋 JENNIFER FITZPATRICK (Officer) plans to sell 10K shares of SIONNA THERAPEUTICS, INC. (at $43.99 each, total $451K) Filed: Jul 06, 2026 | ID: 006887
Read moreDirector Thompson Peter A. 🔴 sold 115.8K shares of Sionna Therapeutics, Inc. (SION) at $45.50 ($5.3M) Transaction Date: Jun 30, 2026 | Filing ID: 000684
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07108153 | Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, … | Phase2 | Cystic Fibrosis (CF) | Active_Not_Recruiting | 2025-11-03 | 2026-07-01 | ClinicalTrials.gov |
| NCT07035990 | Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SIO… | Phase1 | Cystic Fibrosis (CF) | Recruiting | 2025-07-23 | 2026-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | ACTIVE_NOT_RECRUITING | NCT07108153 |
| Placebo SION-109 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-2222 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-451 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-109 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-2222 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-451 | Other | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo-to-match SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| SION-719 | Other | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| Placebo-to-match SION-719 | DRUG | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| SION-719 | DRUG | Phase PHASE2 | Cystic Fibrosis (CF) | RECRUITING | NCT07108153 |
| Placebo SION-109 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-2222 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| Placebo SION-451 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-109 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-2222 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |
| SION-451 | DRUG | Phase PHASE1 | Cystic Fibrosis (CF) | RECRUITING | NCT07035990 |